RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
Syndax is a late stage oncology company whose lead product candidate is entinostat, an oral, selective histone deacetylase inhibitor (HDACi) that is being developed to treat therapy-resistant cancers through an epigenetic mechanism. Entinostat was recently granted Breakthrough Therapy designation by the FDA based on data from the company's completed Phase 2b clinical trial for ER+ metastatic breast cancer.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.